Search Results 771-780 of 17392 for alopecia

  1. A Study to Evaluate DS-8201a Combined with Olaparib in HER2-Expressing Cancers with Expansion in Endometrial Cancer Patients Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer - Mayo Clinic

    Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to grade ≤ 1 or baseline.

  2. Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy - Mayo Clinic

    ... alopecia, anemia and any signs or symptoms of androgen deprivation therapy); Willing to provide tissue and blood samples for correlative research purposes ...

  3. Simulated Teleneonatology Consult - Mayo Clinic

    ... . VID-20442919. Home; Mayo Clinic Teleneonatology Program - Simulated Teleneonatology Consult. 5X Challenge is here!

  4. Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy - Mayo Clinic

    Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (except alopecia). Uncontrolled intercurrent ...

  5. Mayo Clinic

    A picture of a former patient, Cassandra Rohrer, motivates Dr. Nyberg to search for regenerative medicine solutions to help patients needing a liver transplant.

  6. Mayo Clinic

    Mayo Clinic neurosurgeon Kendall H. Lee, M.D., Ph.D., is exploring how deep brain stimulation may help people with neurological-based movement disorders.

  7. Mayo Clinic

    ... . IMG-20469319. Home; cc-hand-green-inhaler_mobile. Final days of 5X Challenge! 5X My Gift! The challenge ends 10/10. Your gift today can have 5X the ...

  8. Cosmetic Center in Arizona - Regenerative medicine services - Mayo Clinic

    Platelet-rich plasma · Stem cell therapy · Hair restoration · Fat grafts or fat injections.

  9. Low-Dose or High-Dose Lenalidomide in Treating Children with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma - Mayo Clinic

    ... alopecia, weight changes and grade I or II lymphopenia. Myelosuppressive chemotherapy: must not have received within 3 weeks of entry onto this study (6 ...

  10. A Study to Evaluate CC-98633 to Treat Subjects with Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

    Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Agree to refrain ...